Study confirms recent guideline changes on metformin use in moderate-to-severe chronic kidney disease.

Researchers complete examination of class of type 2 medication.

Very low incidence of end stage renal disease (ESRD) was found in patients with childhood-onset diabetes type 1 in Norway.

Management of obesity by dietary, pharmacologic, and surgical intervention can provide very positive results.

Which of the classes of drugs have you seen the best results in lowering A1c for type 2 diabetes? DPP-4, GLP-1, or SGLT-2? Follow the link to share your response.

Mrs. O’Doole is a 34-year-old of Irish descent. She works as a florist and is married with three children. She arrives at your clinic for her annual wellness exam. Her blood pressure is 130/84 mmHg, pulse 65, BMI 24 kg/m2 and her physical exam is notable for acne and mild hirsutism. Her only current medication is oral birth control pills. She recalls starting OCP 15 years prior, due to irregular menses. What clinical diagnosis would suggest screening Mrs. Hernandez for type 2 diabetes? A. Thyroid dysfunction B. Cushing syndrome C. Polycystic ovary syndrome D. Premature ovarian failure Follow the link for the answer.

Thomas Seck is Vice President of US Clinical Development and Medical Affairs Primary Care at Boehringer Ingelheim. Thomas earned his medical degree from the University of Mainz in Germany. He completed his residency and fellowship within the Department of Endocrinology and Metabolism, at the University of Heidelberg, Germany.

In this exclusive interview transcript, Thomas Seck discusses new data on the effect of Empagliflozin compared to standard of care for cardiovascular death, for hospitalization of heart failure, for overall mortality independent of changes in blood pressure, in HbA1C and in blood lipids.

In this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about new data on the effects of Empagliflozin and how it compares to the standard of care in terms of cardiovascular death, overall mortality independent of changes in blood pressure, in HbA1C and in blood lipids. 

In part 1 of this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about the Boehringer Ingelheim relationship with Eli Lilly and the cardiovascular effects of certain diabetes medications.